Cargando…

Enterohemorrhagic Escherichia coli Hybrid Pathotype O80:H2 as a New Therapeutic Challenge

We describe the epidemiology, clinical features, and molecular characterization of enterohemorrhagic Escherichia coli (EHEC) infections caused by the singular hybrid pathotype O80:H2, and we examine the influence of antibiotics on Shiga toxin production. In France, during 2005–2014, a total of 54 pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Soysal, Nurcan, Mariani-Kurkdjian, Patricia, Smail, Yasmine, Liguori, Sandrine, Gouali, Malika, Loukiadis, Estelle, Fach, Patrick, Bruyand, Mathias, Blanco, Jorge, Bidet, Philippe, Bonacorsi, Stéphane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994344/
https://www.ncbi.nlm.nih.gov/pubmed/27533474
http://dx.doi.org/10.3201/eid2209.160304
_version_ 1782449311194284032
author Soysal, Nurcan
Mariani-Kurkdjian, Patricia
Smail, Yasmine
Liguori, Sandrine
Gouali, Malika
Loukiadis, Estelle
Fach, Patrick
Bruyand, Mathias
Blanco, Jorge
Bidet, Philippe
Bonacorsi, Stéphane
author_facet Soysal, Nurcan
Mariani-Kurkdjian, Patricia
Smail, Yasmine
Liguori, Sandrine
Gouali, Malika
Loukiadis, Estelle
Fach, Patrick
Bruyand, Mathias
Blanco, Jorge
Bidet, Philippe
Bonacorsi, Stéphane
author_sort Soysal, Nurcan
collection PubMed
description We describe the epidemiology, clinical features, and molecular characterization of enterohemorrhagic Escherichia coli (EHEC) infections caused by the singular hybrid pathotype O80:H2, and we examine the influence of antibiotics on Shiga toxin production. In France, during 2005–2014, a total of 54 patients were infected with EHEC O80:H2; 91% had hemolytic uremic syndrome. Two patients had invasive infections, and 2 died. All strains carried stx2 (variants stx2a, 2c, or 2d); the rare intimin gene (eae-ξ); and at least 4 genes characteristic of pS88, a plasmid associated with extraintestinal virulence. Similar strains were found in Spain. All isolates belonged to the same clonal group. At subinhibitory concentrations, azithromycin decreased Shiga toxin production significantly, ciprofloxacin increased it substantially, and ceftriaxone had no major effect. Antibiotic combinations that included azithromycin also were tested. EHEC O80:H2, which can induce hemolytic uremic syndrome complicated by bacteremia, is emerging in France. However, azithromycin might effectively combat these infections.
format Online
Article
Text
id pubmed-4994344
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-49943442016-09-08 Enterohemorrhagic Escherichia coli Hybrid Pathotype O80:H2 as a New Therapeutic Challenge Soysal, Nurcan Mariani-Kurkdjian, Patricia Smail, Yasmine Liguori, Sandrine Gouali, Malika Loukiadis, Estelle Fach, Patrick Bruyand, Mathias Blanco, Jorge Bidet, Philippe Bonacorsi, Stéphane Emerg Infect Dis Research We describe the epidemiology, clinical features, and molecular characterization of enterohemorrhagic Escherichia coli (EHEC) infections caused by the singular hybrid pathotype O80:H2, and we examine the influence of antibiotics on Shiga toxin production. In France, during 2005–2014, a total of 54 patients were infected with EHEC O80:H2; 91% had hemolytic uremic syndrome. Two patients had invasive infections, and 2 died. All strains carried stx2 (variants stx2a, 2c, or 2d); the rare intimin gene (eae-ξ); and at least 4 genes characteristic of pS88, a plasmid associated with extraintestinal virulence. Similar strains were found in Spain. All isolates belonged to the same clonal group. At subinhibitory concentrations, azithromycin decreased Shiga toxin production significantly, ciprofloxacin increased it substantially, and ceftriaxone had no major effect. Antibiotic combinations that included azithromycin also were tested. EHEC O80:H2, which can induce hemolytic uremic syndrome complicated by bacteremia, is emerging in France. However, azithromycin might effectively combat these infections. Centers for Disease Control and Prevention 2016-09 /pmc/articles/PMC4994344/ /pubmed/27533474 http://dx.doi.org/10.3201/eid2209.160304 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research
Soysal, Nurcan
Mariani-Kurkdjian, Patricia
Smail, Yasmine
Liguori, Sandrine
Gouali, Malika
Loukiadis, Estelle
Fach, Patrick
Bruyand, Mathias
Blanco, Jorge
Bidet, Philippe
Bonacorsi, Stéphane
Enterohemorrhagic Escherichia coli Hybrid Pathotype O80:H2 as a New Therapeutic Challenge
title Enterohemorrhagic Escherichia coli Hybrid Pathotype O80:H2 as a New Therapeutic Challenge
title_full Enterohemorrhagic Escherichia coli Hybrid Pathotype O80:H2 as a New Therapeutic Challenge
title_fullStr Enterohemorrhagic Escherichia coli Hybrid Pathotype O80:H2 as a New Therapeutic Challenge
title_full_unstemmed Enterohemorrhagic Escherichia coli Hybrid Pathotype O80:H2 as a New Therapeutic Challenge
title_short Enterohemorrhagic Escherichia coli Hybrid Pathotype O80:H2 as a New Therapeutic Challenge
title_sort enterohemorrhagic escherichia coli hybrid pathotype o80:h2 as a new therapeutic challenge
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994344/
https://www.ncbi.nlm.nih.gov/pubmed/27533474
http://dx.doi.org/10.3201/eid2209.160304
work_keys_str_mv AT soysalnurcan enterohemorrhagicescherichiacolihybridpathotypeo80h2asanewtherapeuticchallenge
AT marianikurkdjianpatricia enterohemorrhagicescherichiacolihybridpathotypeo80h2asanewtherapeuticchallenge
AT smailyasmine enterohemorrhagicescherichiacolihybridpathotypeo80h2asanewtherapeuticchallenge
AT liguorisandrine enterohemorrhagicescherichiacolihybridpathotypeo80h2asanewtherapeuticchallenge
AT goualimalika enterohemorrhagicescherichiacolihybridpathotypeo80h2asanewtherapeuticchallenge
AT loukiadisestelle enterohemorrhagicescherichiacolihybridpathotypeo80h2asanewtherapeuticchallenge
AT fachpatrick enterohemorrhagicescherichiacolihybridpathotypeo80h2asanewtherapeuticchallenge
AT bruyandmathias enterohemorrhagicescherichiacolihybridpathotypeo80h2asanewtherapeuticchallenge
AT blancojorge enterohemorrhagicescherichiacolihybridpathotypeo80h2asanewtherapeuticchallenge
AT bidetphilippe enterohemorrhagicescherichiacolihybridpathotypeo80h2asanewtherapeuticchallenge
AT bonacorsistephane enterohemorrhagicescherichiacolihybridpathotypeo80h2asanewtherapeuticchallenge